{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T22:50:16Z","timestamp":1769640616515,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,2,17]],"date-time":"2014-02-17T00:00:00Z","timestamp":1392595200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","cysticfibrosisjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.jcf.2014.01.014","type":"journal-article","created":{"date-parts":[[2014,2,22]],"date-time":"2014-02-22T21:45:14Z","timestamp":1393105514000},"page":"428-434","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Safety of inhaled (Tobi\u00ae) and intravenous tobramycin in young children with cystic fibrosis"],"prefix":"10.1016","volume":"13","author":[{"given":"Stefanie","family":"Hennig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"McKay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanna","family":"Vidmar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonya","family":"Stacey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joyce","family":"Cheney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire E.","family":"Wainwright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jcf.2014.01.014_bb0005","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJM199901073400104","article-title":"Intermittent administration of inhaled tobramycin in patients with cystic fibrosis","volume":"340","author":"Ramsey","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2014.01.014_bb0010","first-page":"CD004197","article-title":"Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis","volume":"4","author":"Langton","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"22","key":"10.1016\/j.jcf.2014.01.014_bb0015","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.2165\/00003495-200363220-00015","article-title":"Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis","volume":"63","author":"Cheer","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.jcf.2014.01.014_bb0020","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/j.1552-4604.1994.tb03995.x","article-title":"Absolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosis","volume":"34","author":"Cooney","year":"1994","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.jcf.2014.01.014_bb0025","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0378-4274(90)90033-I","article-title":"Aminoglycoside-induced ototoxicity","volume":"52","author":"Govaerts","year":"1990","journal-title":"Toxicol Lett"},{"issue":"5","key":"10.1016\/j.jcf.2014.01.014_bb0030","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1128\/AAC.43.5.1003","article-title":"Aminoglycosides: nephrotoxicity","volume":"43","author":"Mingeot-Leclercq","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"issue":"6B","key":"10.1016\/j.jcf.2014.01.014_bb0035","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/0002-9343(86)90497-3","article-title":"Aminoglycoside toxicity in infants and children","volume":"80","author":"McCracken","year":"1986","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.jcf.2014.01.014_bb0040","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0924-8579(02)00030-4","article-title":"Extended interval aminoglycoside dosing: from concept to clinic","volume":"19","author":"Maglio","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jcf.2014.01.014_bb0045","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1164\/rccm.200208-855OC","article-title":"Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis","volume":"167","author":"Gibson","year":"2003","journal-title":"Am J Respir Crit Care"},{"issue":"9","key":"10.1016\/j.jcf.2014.01.014_bb0050","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1001\/archpediatrics.2011.136","article-title":"Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis","volume":"165","author":"Treggiari","year":"2011","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"2","key":"10.1016\/j.jcf.2014.01.014_bb0055","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ppul.1950060207","article-title":"Long-term tobramycin aerosol therapy in cystic fibrosis","volume":"6","author":"Steinkamp","year":"1989","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"10.1016\/j.jcf.2014.01.014_bb0060","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ppul.1950070110","article-title":"Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa","volume":"7","author":"MacLusky","year":"1989","journal-title":"Pediatr Pulmonol"},{"issue":"9286","key":"10.1016\/j.jcf.2014.01.014_bb0065","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(01)06124-4","article-title":"Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis","volume":"358","author":"Ratjen","year":"2001","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jcf.2014.01.014_bb0070","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jama.2011.954","article-title":"Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial","volume":"306","author":"Wainwright","year":"2011","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.jcf.2014.01.014_bb0075","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/cpt1977213362","article-title":"Kinetic model for gentamicin dosing with the use of individual patient parameters","volume":"21","author":"Sawchuk","year":"1977","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.jcf.2014.01.014_bb0080","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.ftd.0000155341.16361.62","article-title":"Misleading high tobramycin plasma concentrations can be caused by skin contamination of fingerprick blood following inhalation of nebulized tobramycin (TOBI): a short report","volume":"27","author":"Redmann","year":"2005","journal-title":"Ther Drug Monit"},{"issue":"11","key":"10.1016\/j.jcf.2014.01.014_bb0085","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.2215\/CJN.01640309","article-title":"Measurement and estimation of GFR in children and adolescents","volume":"4","author":"Schwartz","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.jcf.2014.01.014_bb0090","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/infdis\/155.1.93","article-title":"Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration","volume":"155","author":"Moore","year":"1987","journal-title":"J Infect Dis"},{"issue":"9459","key":"10.1016\/j.jcf.2014.01.014_bb0095","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0140-6736(05)70798-4","article-title":"Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis\u2014the TOPIC study: a randomised controlled trial","volume":"365","author":"Smyth","year":"2005","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jcf.2014.01.014_bb0100","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/thx.2009.121657","article-title":"Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial","volume":"65","author":"Ratjen","year":"2010","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.jcf.2014.01.014_bb0105","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1067\/mpd.2001.117785","article-title":"Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis","volume":"139","author":"Rosenfeld","year":"2001","journal-title":"J Pediatr"},{"issue":"1","key":"10.1016\/j.jcf.2014.01.014_bb0110","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1378\/chest.122.1.219","article-title":"Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis","volume":"122","author":"Geller","year":"2002","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.jcf.2014.01.014_bb0115","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/(SICI)1099-0496(200001)29:1<43::AID-PPUL8>3.0.CO;2-G","article-title":"Falsely elevated serum tobramycin concentrations in cystic fibrosis patients treated with concurrent intravenous and inhaled tobramycin","volume":"29","author":"Elidemir","year":"2000","journal-title":"Pediatr Pulmonol"},{"issue":"22","key":"10.1016\/j.jcf.2014.01.014_bb0120","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.2165\/00003495-200363220-00015","article-title":"Inhaled tobramycin (TOBI\u00ae)","volume":"63","author":"Cheer","year":"2003","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.jcf.2014.01.014_bb0125","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1128\/AAC.31.4.594","article-title":"Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis","volume":"31","author":"Pedersen","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.jcf.2014.01.014_bb0130","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/jac\/5.3.257","article-title":"Tobramycin ototoxicity. Repeated courses of high dosage treatment in children with cystic fibrosis.","volume":"5","author":"Thomsen","year":"1979","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.jcf.2014.01.014_bb0135","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1093\/jac\/31.3.429","article-title":"Assessment of potential ototoxicity following high-dose nebulized tobramycin in patients with cystic fibrosis","volume":"31","author":"Mukhopadhyay","year":"1993","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.jcf.2014.01.014_bb0140","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1034\/j.1399-3003.2000.16d30.x","article-title":"Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus","volume":"16","author":"Doring","year":"2000","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.jcf.2014.01.014_bb0145","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/00125817-200209000-00004","article-title":"Genetic susceptibility to aminoglycoside ototoxicity: how many are at risk?","volume":"4","author":"Tang","year":"2002","journal-title":"Genet Med"},{"issue":"9","key":"10.1016\/j.jcf.2014.01.014_bb0150","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1128\/AAC.45.9.2502-2509.2001","article-title":"Occurrence and risk of cochleotoxicity in cystic fibrosis patients receiving repeated high-dose aminoglycoside therapy","volume":"45","author":"Mulheran","year":"2001","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199314000393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199314000393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T22:07:51Z","timestamp":1565215671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199314000393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S1569199314000393"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2014.01.014","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of inhaled (Tobi\u00ae) and intravenous tobramycin in young children with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2014.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}